Showing 611-620 of 20873 results for "".
- HER2 Amplification Extends Across Tumor Types, Highlighting New Opportunities for Precision Oncologyhttps://reachmd.com/news/her2-amplification-extends-across-tumor-types-highlighting-new-opportunities-for-precision-oncology/2486472/Key Takeaways HER2 amplification was identified in 5.7% of nearly 90,000 solid tumors in Japan, extending well be
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://reachmd.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- A New Biomarker Helps Detect Kidney Fibrosis in Transplant Patients Without Invasive Procedureshttps://reachmd.com/news/a-new-biomarker-helps-detect-kidney-fibrosis-in-transplant-patients-without-invasive-procedures/2468714/by Germans Trias i Pujol Research Institute
- Renal Clues at Diagnosis: Uncovering Kidney Risk in New-Onset Diabeteshttps://reachmd.com/news/renal-health-and-guideline-compliance-in-newly-diagnosed-diabetes-mellitus/2474259/When patients are first diagnosed with diabetes mellitus, the clinical lens often zooms in on blood glucose control. But a growing body of evidence suggests another vital parameter deserves early attention: renal health. Research now points to a high prevalence of
- New UH Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://reachmd.com/news/new-uh-study-targets-early-signs-of-vision-loss-in-diabetic-patients/2467853/A $3.3 million study at the University of Houston College of Optometry will track the health of patients with prediabetes and diabetes to find out who might develop eye problems and be at risk for future vision loss. The study is being led by Wendy Harrison, associate professor, and is under
- EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2https://reachmd.com/news/edta-chelation-no-help-in-cutting-cv-outcomes-after-mi-in-diabetic-patients-tact2/2462631/ATLANTA, GA—More than a decade after the TACT trial reported an astonishing reduction in cardiovascular events post-MI with heavy metal chelation in a subset of diabetic patients, the TACT2 trial, designed to test edetate disodium (EDTA) solely in a diabetic popu
- AMT-191 Phase I/IIa Update: Durable α‑Gal A, Hepatic Signals, and Nephrology Implicationshttps://reachmd.com/news/amt-191-phase-iiia-update-durable-gal-a-hepatic-signals-and-nephrology-implications/2485605/Preliminary open-label data from the
- Exploring Social Determinants of Health and Treatment Disparities in Stage I Lung Cancer: Insights from Ontariohttps://reachmd.com/news/exploring-social-determinants-of-health-and-treatment-disparities-in-stage-i-lung-cancer-insights-from-ontario/2484983/An Ontario population-based cohort shows material deprivation is linked to lower receipt of surgical resection and greater reliance on radiotherapy or no treatment among adults with early-stage lung cancer, as reported in the
- Ethris Doses First Patient with Antiviral mRNA Drug in Phase I Asthma Trialhttps://reachmd.com/news/ethris-doses-first-patient-with-antiviral-mrna-drug-in-phase-i-asthma-trial/2463243/
- MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Studyhttps://reachmd.com/news/mira-pharmaceuticals-achieves-100-reversal-of-neuropathic-pain-with-oral-ketamir-2-in-breakthrough-study/2468049/Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pha